Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS venture cleans up acid mine drainage
2015-07-06

The system that puts oxygen back into the water.

Photo: Supplied

South Africa is one of the most important mining countries in the world, beginning in the 1870s. Although the mining industry has been responsible for significant development and employment, it pollutes the environment and waters sources. Through the joint effort of a well-known mining company, the University of the Free State, and the Technology Innovation Agency (UFS/TIA) SAENSE Group, a new treatment for Acid Mine Drainage (AMD) has been developed.

The system treats the major contaminants found in acid mining wastewater effectively.  
 
The UFS remediation systems use a reservoir tank into which the AMD is pumped. The water then flows passively (without using energy) to the Barium Carbonate Dispersed Alkaline Substrate (BDAS) system. The metals and anions in the AMD react chemically with the barium carbonate and precipitate (form solids). The solids stay in the tank while the clean water is released.

The efficacy and applicability of the research was demonstrated on site in Belfast, Mpumalanga where the team constructed a pilot plant in July 2014. This patented technology has treated 1 814 400 litres of Acid Mine Drainage to date with an outflow water quality that satisfies the South African National Standards (SANS) 241:2006 & 2011 regulations for drinking water.   

Rohan Posthumus from the (UFS/TIA) SAENSE Group said: “At this stage, we do not recommend that the water should be used as drinking water, but certainly it can lower water usage in mines while finding application in dust suppression of washing processes. The team would like to complete a full characterisation of the final released water. There are currently no toxic by-products formed, and even very basic filtration can make the outflow drinking water.”

Prof Esta van Heerden’s research group from the Department of Microbial, Biochemical, and Food Biotechnology has been working on AMD research for some time, but the development of the BDAS system was started in 2013 by post-doctoral student, Dr Julio Castillo, and his junior researcher, Rohan Posthumus.

The data from the BDAS system have led to two publications in peer-reviewed journals as well as a registered patent.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept